SCHEMBL4353970

SCHEMBL4353970

CCOC(=O)CCNC(=O)Nc1cc(Br)cc(F)c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
GPR35 Q9HC97 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
PTPN7 P35236 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
KDM4E B2RXH2 4/20 0.36
HTT P42858 2/20 0.36
NLRP3 Q96P20 1/20 0.36
HSD17B10 Q99714 2/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ITGB3 P05106 1/20 0.35
ITGAV P06756 1/20 0.35
HPGD P15428 3/20 0.35
MAPT P10636 2/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4358426 0.88 ALDH1A1 (0.43) ALDH1A1PTPN7KMT2AMEN1KDM4E
SCHEMBL6228224 0.82 EPHX2 (0.47) ALDH1A1KMT2AMEN1HTTMAPT
SCHEMBL4351702 0.81 ALDH1A1 (0.52) ALDH1A1PTPN7KMT2AMEN1KDM4E
SCHEMBL27761084 0.81 EPHX2 (0.50) ALDH1A1HTTHPGDMAPTEPHX2
SCHEMBL4346935 0.81 ALDH1A1 (0.49) ALDH1A1PTPN7KMT2AMEN1KDM4E
SCHEMBL4347794 0.80 EPHX2 (0.55) ALDH1A1HTTHPGDEPHX2SMN1; SMN2
SCHEMBL4351254 0.77 HTT (0.47) ALDH1A1GPR35CYP1A2CYP2C19PTPN7
SCHEMBL4342431 0.76 ALDH1A1 (0.52) ALDH1A1CYP1A2CYP3A4CYP2C19PTPN7
SCHEMBL4346301 0.76 MEN1 (0.46) ALDH1A1CYP1A2CYP2C19PTPN7KMT2A
SCHEMBL4359582 0.73 ALDH1A1 (0.52) ALDH1A1PTPN7KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 ALDH1A1 2565/4885GPR35 1276/4885CYP1A2 215/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 ALDH1A1 2767/4885GPR35 1415/4885CYP1A2 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.